LC
Arvinas Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Vepdegestrant (ARV-471) | ER+/HER2- Advanced Breast Cancer | Phase 3 |
| ARV-766 | Metastatic Castration-Resistant Prostate Cancer | Phase 2 |
| Bavdegalutamide (ARV-110) | Metastatic Castration-Resistant Prostate Cancer | Phase 2 |
| ARV-102 | Parkinson's Disease | Phase 1 |
| ARV-393 | Undisclosed Oncology | Phase 1 |
| ARV-6723 | Undisclosed Oncology | Phase 1 |
| ARV-806 | Undisclosed Oncology | Phase 1 |
| ARV-027 | Undisclosed Oncology | Phase 1 |
Leadership Team at Arvinas
JG
John G. Houston
President, CEO, and Chair of the Board
CC
Craig Crews
Founder, Executive Director, Chief Scientific Advisor
RM
Ronald M. Peck
Chief Medical Officer
SA
Sean A. Cassidy
Chief Financial Officer
IT
Ian Taylor
Chief Scientific Officer
SA
Sunil Agarwal
President of R&D